Navigating the Next Wave in BTK Inhibition Strategies: Maximizing Clinical Benefit in CLL and MCL, What’s Next in B-Cell Malignancies

Welcome and Introductions

Module 1: Maximizing Clinical Benefit of BTKi Therapeutic Options in CLL/SLL, Including Richter Transformation

Module 2: Recent Evidence for BTKi Strategies in Waldenström Macroglobulinemia

Module 3: Best Practices for Utilization of BTKi Strategies in MCL

Module 4: Recent Evidence for BTKi Strategies in Other DLBCL and FL

Post-Test, Conclusions, and Closing Remarks